BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/3/2016 11:05:00 AM | Browse: 1511 | Download: 3236
 |
Received |
|
2015-08-02 12:43 |
|
Peer-Review Started |
|
2015-08-03 11:45 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2015-09-15 14:30 |
|
Revised |
|
2015-10-24 03:40 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2015-11-23 18:00 |
|
Second Decision by Editor-in-Chief |
|
2015-11-23 18:35 |
|
Final Decision by Editorial Office Director |
|
2015-12-04 16:19 |
|
Articles in Press |
|
2015-12-04 16:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-02-29 09:24 |
|
Publish the Manuscript Online |
|
2016-03-03 11:05 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Christine U Oramasionwu, Angela DM Kashuba, Sonia Napravnik, David A Wohl, Lu Mao and Adaora A Adimora |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| University of North Carolina at Chapel Hill Center for AIDS Research an NIH |
P30 AI50410(to Dr. Oramasionwu) |
| NIH Loan Repayment Program (LRP) through the National Institute on Minority Health and Health Disparities |
L60 MD003770(to Dr. Oramasionwu) |
|
| Corresponding Author |
Christine U Oramasionwu, PharmD, PhD, Assistant Professor, UNC Eshelman School of Pharmacy, University of North Carolina, Kerr Hall 2215, Chapel Hill, NC 27599, United States. oramsc@unc.edu
|
| Key Words |
Human immunodeficiency virus; Hepatitis C virus; Co-infection; Antiviral therapy; Race |
| Core Tip |
Historically, hepatitis C virus (HCV) treat-ment rates have been low in patients with human immunodeficiency virus (HIV) co-infection, especially for African-American patients. Identifying the reasons for treatment non-initiation may help improve treatment rates among racially and ethnic minorities. In our study of patients with HIV/HCV coinfection, non-modifiable medical reasons, potentially modifiable medical reasons, and non-medical reasons for non-treatment were common among all patients, regardless of their race/ethnicity. There is a need to recognize and overcome potential treatment barriers in order to improve HCV treatment uptake in this patient population.
|
| Publish Date |
2016-03-03 11:05 |
| Citation |
Oramasionwu CU, Kashuba ADM, Napravnik S, Wohl DA, Mao L, Adimora AA. Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection. World J Hepatol 2016; 8(7): 368-375 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i7/368.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i7.368 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
